Clotrimazole - Redpharm Drug

Manufacturer
Redpharm Drug
Effective date
2026-06-09
Label type
HUMAN PRESCRIPTION DRUG LABEL
Version
1
Source
daily-update
Hydrated at
2026-06-11 05:11:34

Label at a glance#

ProductClotrimazole
Active ingredientCLOTRIMAZOLE
Label structure14 sections

Indications and uses

Clotrimazole cream USP is indicated for the topical treatment of candidiasis due to Candida albicans and tinea versicolor due to Malassezia furfur. Clotrimazole is also available as a nonprescription item which is indicated for the topical treatment of the following dermal infections: tinea pedis, tinea cruris, and tinea corporis due to Trichophyton rubrum, Trichophyton mentagrophytes , Epidermophyton floccosum , ...

Dosage and administration

Gently massage sufficient clotrimazole cream into the affected and surrounding skin areas twice a day, in the morning and evening. Clinical improvement, with relief of pruritis, usually occurs within the first week of treatment with clotrimazole cream. If the patient shows no clinical improvement after four weeks of treatment with clotrimazole cream, the diagnosis should be reviewed.

Storage and handling

Store between 2°C- 30°C (36°F -86°F).

Label contents#

Full prescribing information#

SPL UNCLASSIFIED SECTION

For external use only
Not for Ophthalmic Use

Rx only

DESCRIPTION

DESCRIPTION SECTION

Clotrimazole cream USP, 1% contains clotrimazole USP, a synthetic antifungal agent having the chemical name {1-(o-Chloro-α, α-diphenylbenzyl)imidazole}; the molecular formula C 22H 17ClN 2; a molecular weight of 344.84; and the structural formula:

structure
structure

Clotrimazole USP is an odorless, white crystalline substance. It is practically insoluble in water, sparingly soluble in ether and very soluble in polyethylene glycol 400, ethanol and chloroform.

Each gram of clotrimazole cream USP contains 10 mg clotrimazole USP, dispersed in a vanishing cream base of sorbitan monostearate, polysorbate 60, cetyl esters wax, cetostearyl alcohol, octyldodecanol, purified water, and benzyl alcohol (1%) as preservative.

CLINICAL PHARMACOLOGY

CLINICAL PHARMACOLOGY SECTION

Clotrimazole is a broad-spectrum antifungal agent that is used for the treatment of dermal infections caused by various species of pathogenic dermatophytes, yeasts, and Malassezia furfur. The primary action of clotrimazole is against dividing and growing organisms.

In vitro,clotrimazole exhibits fungistatic and fungicidal activity against isolates of Trichophyton rubrum, Trichophyton mentagrophytes, Epidermophyton floccosum, Microsporum canisand Candidaspecies including Candida albicans. In general, the in vitroactivity of clotrimazole corresponds to that of tolnaftate and griseofulvin against the mycelia of dermatophytes ( Trichophyton, Microsporum,and Epidermophyton), and to that of the polyenes (amphotericin B and nystatin) against budding fungi ( Candida). Using an in vivo(mouse) and an in vitro(mouse kidney homogenate) testing system, clotrimazole and micronazole were equally effective in preventing the growth of the pseudomycelia and mycelia of Candida albicans.

Strains of fungi having a natural resistance to clotrimazole are rare. Only a single isolate of Candida guilliermondihas been reported to have primary resistance to clotrimazole.

No single-step or multiple-step resistance to clotrimazole has developed during successive passages of Candida albicansand Trichophyton mentagrophytes. No appreciable change in sensitivity was detected after successive passage of isolates of C. albicans, C. krusei, or C. pseudotropicalisin liquid or solid media containing clotrimazole. Also, resistance could not be developed in chemically induced mutant strains of polyene-resistant isolates of C. albicans. Slight, reversible resistance was noted in three isolates of C. albicanstested by one investigator. There is a single report that records the clinical emergence of C. albicansstrain with considerable resistance to flucytosine and micronazole, and with cross-resistance to clotrimazole, the strain remained sensitive to nystatin and amphotericin B.

In studies of the mechanism of action, the minimum fungicide concentration of clotrimazole caused leakage of intracellular phosphorus compounds into the ambient medium with concomitant breakdown of cellular nucleic acids and accelerated potassium efflux. Both these events began rapidly and extensively after addition of the drug.

Clotrimazole appears to be well absorbed in humans following oral administration and is eliminated mainly as inactive metabolites. Following topical and vaginal administration, however, clotrimazole appears to be minimally absorbed.

Six hours after the application of radioactive clotrimazole 1% cream and 1% solution onto intact and acutely inflamed skin, the concentration of clotrimazole varied from 100 mcg/cm 3in the stratum corneum to 0.5 to 1 mcg/cm 3in the stratum reticulare, and 0.1 mcg/cm 3in the subcutis. No measurable amount of radioactivity (≤0.001 mcg/mL) was found in the serum within 48 hours after application under occlusive dressing of 0.5 mL of the solution or 0.8 g of the cream. Only 0.5% or less of the applied radioactivity was excreted in the urine.

Following intravaginal administration of 100 mg 14C-clotrimazole vaginal tablets to nine adult females, an average peak serum level, corresponding to only 0.03 μg equivalent/mL of clotrimazole, was reached one to two days after application. After intravaginal administration of 5 g of 1% 14C-clotrimazole vaginal cream containing 50 mg active drug, to five subjects (one with candidal colpitis), serum levels corresponding to approximately 0.01 μg equivalents/mL were reached between 8 and 24 hours after application.

INDICATIONS AND USAGE

INDICATIONS & USAGE SECTION

Clotrimazole cream USP is indicated for the topical treatment of candidiasis due to Candida albicansand tinea versicolor due to Malassezia furfur.

Clotrimazole is also available as a nonprescription item which is indicated for the topical treatment of the following dermal infections: tinea pedis, tinea cruris, and tinea corporis due to Trichophyton rubrum, Trichophyton mentagrophytes, Epidermophyton floccosum, and Microsporum canis.

CONTRAINDICATIONS

CONTRAINDICATIONS SECTION

Clotrimazole cream is contraindicated in individuals sensitive to its components.

WARNINGS

WARNINGS SECTION

Clotrimazole cream is not for ophthalmic use.

PRECAUTIONS

PRECAUTIONS SECTION

General:

GENERAL PRECAUTIONS SECTION

If irritation or sensitivity develops with the use of clotrimazole cream, treatment should be discontinued and appropriate therapy instituted.

Information for Patients:

INFORMATION FOR PATIENTS SECTION

The patient should be advised to:

  1. Use the medication for the full treatment time even though the symptoms may have improved. Notify the physician if there is no improvement after four weeks of treatment.
  2. Inform the physician if the area of application shows signs of increased irritation (redness, itching, burning, blistering, swelling, oozing) indicative of possible sensitization.
  3. Avoid the use of occlusive wrappings or dressings.
  4. Avoid sources of infection or reinfection.

Laboratory Tests

LABORATORY TESTS SECTION

If there is lack of response to clotrimazole cream, appropriate microbiological studies should be repeated to confirm the diagnosis and rule out other pathogens before instituting another course of antimycotic therapy.

Drug Interactions

DRUG INTERACTIONS SECTION

Synergism or antagonism between clotrimazole and nystatin, or amphotericin B, or flucytosine against strains of C. albicanshas not been reported.

Carcinogenesis, Mutagenesis, Impairment of Fertility

CARCINOGENESIS & MUTAGENESIS & IMPAIRMENT OF FERTILITY SECTION

An 18-month oral dosing study with clotrimazole in rats has not revealed any carcinogenic effect.

In tests for mutagenesis, chromosomes of the spermatophores of Chinese hamsters which had been exposed to clotrimazole were examined for structural changes during the metaphase. Prior to testing, the hamsters had received five oral clotrimazole doses of 100 mg/kg body weight. The results of this study showed that clotrimazole had no mutagenic effect.

Usage in Pregnancy: Pregnancy Category B

PREGNANCY SECTION

The disposition of 14C-clotrimazole has been studied in humans and animals. Clotrimazole is very poorly absorbed following dermal application or intravaginal administration to humans. (See CLINICAL PHARMACOLOGY)

In clinical trials, use of vaginally applied clotrimazole in pregnant women in their second and third trimesters has not been associated with ill effects. There are, however, no adequate and well-controlled studies in pregnant women during the first trimester of pregnancy.

Studies in pregnant rats with intravaginaldoses up to 100 mg/kg have revealed no evidence of harm to the fetus due to clotrimazole.

High oraldoses of clotrimazole in rats and mice ranging from 50 to 120 mg/kg resulted in embroyotoxicity (possible secondary to maternal toxicity), impairment of mating, decreased litter size and number of viable young and decreased pup survival to weaning. However, clotrimazole was notteratogenic in mice, rabbits and rats at oral doses up to 200, 180 and 100 mg/kg, respectively. Oral absorption in the rat amounts to approximately 90% of the administered dose.

Because animal reproduction studies are not always predictive of human response, this drug should be used only if clearly indicated during the first trimester of pregnancy.

Nursing Mothers

NURSING MOTHERS SECTION

It is not known whether this drug is excreted in human milk, caution should be exercised when clotrimazole is used by a nursing woman.

Pediatric Use

PEDIATRIC USE SECTION

Safety and effectiveness in children have been established for clotrimazole when used as indicated and in the recommended dosage.

ADVERSE REACTIONS

ADVERSE REACTIONS SECTION

The following adverse reactions have been reported in connection with the use of this product: erythema, stinging, blistering, peeling, edema, pruritis, urticaria, burning, and general irritation of the skin.

OVERDOSAGE

OVERDOSAGE SECTION

Acute overdosage with topical application of clotrimazole is unlikely and would not be expected to lead to a life-threatening situation.

DOSAGE AND ADMINISTRATION

DOSAGE & ADMINISTRATION SECTION

Gently massage sufficient clotrimazole cream into the affected and surrounding skin areas twice a day, in the morning and evening.

Clinical improvement, with relief of pruritis, usually occurs within the first week of treatment with clotrimazole cream. If the patient shows no clinical improvement after four weeks of treatment with clotrimazole cream, the diagnosis should be reviewed.

HOW SUPPLIED

HOW SUPPLIED SECTION

Clotrimazole cream USP, 1% is supplied in 15, 30, 45 and (2 x 45) gram tubes.

NDC 68462-181-17 (15 g)
NDC 68462-181-35 (30 g)
NDC 68462-181-47 (45 g)
NDC 68462-181-48 (2 x 45 g)

STORAGE AND HANDLING SECTION

Store between 2°C- 30°C (36°F -86°F).

SPL UNCLASSIFIED SECTION

Distributed by:

glenmarklogo
glenmarklogo

Glenmark Pharmaceuticals Inc., USA
Elmwood Park, NJ 07407

Questions? 1 (888)721-7115
www.glenmarkpharma-us.com

May 2025

Principal Display Panel

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

NDC 68462-181-35
Clotrimazole Cream USP, 1%
For external use only. Not for ophthalmic use.

carton
carton

Product Linked Resources#

Resource, Code type, Value table
ResourceCode typeValueEquivalent identifiersSource image
BarcodeEAN-130368462181355GTIN-13: 0368462181355
EAN-13: 0368462181355
GTIN-12: 368462181355
UPC-A: 368462181355
GTIN storage (14 digits): 00368462181355
carton.jpg

DailyMed Billing Units#

Package NDC, Billing unit, Product NDC table
Package NDCBilling unitProduct NDCDailyMed indexing SPLSPL versionEffective
68462-181-17GM - Gram68462-181079f8f88-97d0-458a-876e-6a53ab7fd3ea12012-07-24
68462-181-35GM - Gram68462-181892db13f-41ba-47e9-b5d0-b5c8c146116712012-07-24
68462-181-47GM - Gram68462-181b4b331fb-c381-4258-b371-ef65c604e88612012-07-24

Products#

Every source-derived product name is available through these pages.

DailyMed product names page 1 of 1 · 7 matching rows.

NDC Codes#

Product NDC, Package NDC table
Product NDCPackage NDC
67296-225267296-2252-3
68462-181

Ingredients#

Every source-derived ingredient row is available through these pages.

DailyMed ingredient rows page 1 of 1 · 7 matching rows.

Source Document#

Source XML

Orange Book application contexts#

All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.

Orange Book application contexts page 1 of 1 · 1 matching rows.

Source provenance: Browse the complete Orange Book source catalog · source snapshot 44.

Orange Book products#

Current product rows page 1 of 1 · 1 matching rows.

Application-product, Trade name, Ingredient table
Application-productTrade nameIngredientStrengthDosage form / routeTE codesRLD / RSApproval date
A090219-001CLOTRIMAZOLECLOTRIMAZOLE1%CREAM / TOPICALAB2010-08-03

Therapeutic equivalence codes#

Current TE-code rows page 1 of 1 · 1 matching rows.

Application-product, TE code table
Application-productTE code
A090219-001AB

Observed Orange Book product history#

Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.

Product history page 1 of 2 · 44 observed states.

Captured, Edition, Application-product table
CapturedEditionApplication-productTrade nameStrengthDosage form / routeProduct TE source textRLD / RSApproval dateSource SHA-256
2026-10-15 13:18:302026-09A090219-001CLOTRIMAZOLE1%CREAM / TOPICALAB2010-08-03c2088c7a36db…
2026-09-14 22:38:342026-08A090219-001CLOTRIMAZOLE1%CREAM / TOPICALAB2010-08-0384e616aacf4f…
2026-08-18 06:07:402026-07A090219-001CLOTRIMAZOLE1%CREAM / TOPICALAB2010-08-03caaa826d4ba7…
2026-02-19 14:30 UTC2026-02A090219-001CLOTRIMAZOLE1%CREAM / TOPICALAB2010-08-03011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12A090219-001CLOTRIMAZOLE1%CREAM / TOPICALAB2010-08-0331067a03dcf5…
2025-08-23 18:47 UTC2025-08A090219-001CLOTRIMAZOLE1%CREAM / TOPICALAB2010-08-036a471c1ec25d…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03A090219-001CLOTRIMAZOLE1%CREAM / TOPICALAB2010-08-03fd3edfee7708…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02A090219-001CLOTRIMAZOLE1%CREAM / TOPICALAB2010-08-03b8a1b40f171c…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01A090219-001CLOTRIMAZOLE1%CREAM / TOPICALAB2010-08-0303ed91905a0d…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12A090219-001CLOTRIMAZOLE1%CREAM / TOPICALAB2010-08-032680178bc6a6…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09A090219-001CLOTRIMAZOLE1%CREAM / TOPICALAB2010-08-035bbf6a4d5a75…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11A090219-001CLOTRIMAZOLE1%CREAM / TOPICALAB2010-08-03d8e5a09893c0…
2024-10-29 15:01 UTC2024-10A090219-001CLOTRIMAZOLE1%CREAM / TOPICALAB2010-08-03d06236e962d9…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08A090219-001CLOTRIMAZOLE1%CREAM / TOPICALAB2010-08-0379d66fd596c7…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07A090219-001CLOTRIMAZOLE1%CREAM / TOPICALAB2010-08-03301d65b070ca…
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06A090219-001CLOTRIMAZOLE1%CREAM / TOPICALAB2010-08-031e350fbaab3a…
2024-05-31 18:47 UTC2024-05A090219-001CLOTRIMAZOLE1%CREAM / TOPICALAB2010-08-038072bd15b7f6…
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06A090219-001CLOTRIMAZOLE1%CREAM / TOPICALAB2010-08-035c6f7cd8ea54…
2022-04-08 23:34 UTC2022-04A090219-001CLOTRIMAZOLE1%CREAM / TOPICALAB2010-08-035d02ea3f76ae…
2022-04-04 05:41 UTC2022-04A090219-001CLOTRIMAZOLE1%CREAM / TOPICALAB2010-08-034b0b4de00fa7…
2019-12-13 00:20 UTC2019-12A090219-001CLOTRIMAZOLE1%CREAM / TOPICALAB2010-08-0374a2ff9319b5…
2022-03-09 01:35 UTC2022-03A090219-001CLOTRIMAZOLE1%CREAM / TOPICALAB2010-08-03bb7c543d1eb4…
2021-12-28 21:50 UTC2021-12A090219-001CLOTRIMAZOLE1%CREAM / TOPICALAB2010-08-03782e0a99824c…
2021-05-05 16:15 UTC · 3 captures of this ZIP2021-05A090219-001CLOTRIMAZOLE1%CREAM / TOPICALAB2010-08-0387673890dc5c…
2021-03-12 10:30 UTC2021-03A090219-001CLOTRIMAZOLE1%CREAM / TOPICALAB2010-08-035aa47cf7b7d7…
2020-12-22 03:56 UTC2020-12A090219-001CLOTRIMAZOLE1%CREAM / TOPICALAB2010-08-038869cabd3fbd…
2020-11-12 02:37 UTC2020-11A090219-001CLOTRIMAZOLE1%CREAM / TOPICALAB2010-08-03c0c555d07b60…
2019-12-14 00:12 UTC2019-12A090219-001CLOTRIMAZOLE1%CREAM / TOPICALAB2010-08-033f01610625f2…
2019-09-15 20:21 UTC2019-09A090219-001CLOTRIMAZOLE1%CREAM / TOPICALAB2010-08-03b00525d2431f…
2019-07-19 19:46 UTC2019-07A090219-001CLOTRIMAZOLE1%CREAM / TOPICALAB2010-08-03ea99ee380514…
2024-03-16 18:09 UTC · 4 captures of this ZIP2024-03A090219-001CLOTRIMAZOLE1%CREAM / TOPICALAB2010-08-036a51e52b5d6a…
2024-02-18 07:12 UTC2024-02A090219-001CLOTRIMAZOLE1%CREAM / TOPICALAB2010-08-031c564ffb4f44…
2023-12-20 04:57 UTC2023-12A090219-001CLOTRIMAZOLE1%CREAM / TOPICALAB2010-08-03ea1830bbd6c7…
2023-11-28 05:40 UTC · 2 captures of this ZIP2023-11A090219-001CLOTRIMAZOLE1%CREAM / TOPICALAB2010-08-03a72a2bbeb626…
2023-10-25 00:34 UTC · 2 captures of this ZIP2023-10A090219-001CLOTRIMAZOLE1%CREAM / TOPICALAB2010-08-039b2671bbb829…
2023-07-15 15:27 UTC · 2 captures of this ZIP2023-07A090219-001CLOTRIMAZOLE1%CREAM / TOPICALAB2010-08-03a67488948f0b…
2023-06-13 01:57 UTC · 3 captures of this ZIP2023-06A090219-001CLOTRIMAZOLE1%CREAM / TOPICALAB2010-08-033f0d92c62455…
2023-05-13 08:27 UTC2023-05A090219-001CLOTRIMAZOLE1%CREAM / TOPICALAB2010-08-03053a50430f4f…
2023-01-26 05:58 UTC2023-01A090219-001CLOTRIMAZOLE1%CREAM / TOPICALAB2010-08-033bdfa0b2c4d7…
2022-11-12 20:34 UTC · 5 captures of this ZIP2022-11A090219-001CLOTRIMAZOLE1%CREAM / TOPICALAB2010-08-033a93d1ddd44b…

Observed Orange Book normalized TE history#

Normalized TE history page 1 of 2 · 44 observed states.

Captured, Edition, Application-product table
CapturedEditionApplication-productTE codeOrderSource SHA-256
2026-10-15 13:18:302026-09A090219-001AB1c2088c7a36db…
2026-09-14 22:38:342026-08A090219-001AB184e616aacf4f…
2026-08-18 06:07:402026-07A090219-001AB1caaa826d4ba7…
2026-02-19 14:30 UTC2026-02A090219-001AB1011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12A090219-001AB131067a03dcf5…
2025-08-23 18:47 UTC2025-08A090219-001AB16a471c1ec25d…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03A090219-001AB1fd3edfee7708…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02A090219-001AB1b8a1b40f171c…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01A090219-001AB103ed91905a0d…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12A090219-001AB12680178bc6a6…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09A090219-001AB15bbf6a4d5a75…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11A090219-001AB1d8e5a09893c0…
2024-10-29 15:01 UTC2024-10A090219-001AB1d06236e962d9…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08A090219-001AB179d66fd596c7…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07A090219-001AB1301d65b070ca…
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06A090219-001AB11e350fbaab3a…
2024-05-31 18:47 UTC2024-05A090219-001AB18072bd15b7f6…
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06A090219-001AB15c6f7cd8ea54…
2022-04-08 23:34 UTC2022-04A090219-001AB15d02ea3f76ae…
2022-04-04 05:41 UTC2022-04A090219-001AB14b0b4de00fa7…
2019-12-13 00:20 UTC2019-12A090219-001AB174a2ff9319b5…
2022-03-09 01:35 UTC2022-03A090219-001AB1bb7c543d1eb4…
2021-12-28 21:50 UTC2021-12A090219-001AB1782e0a99824c…
2021-05-05 16:15 UTC · 3 captures of this ZIP2021-05A090219-001AB187673890dc5c…
2021-03-12 10:30 UTC2021-03A090219-001AB15aa47cf7b7d7…
2020-12-22 03:56 UTC2020-12A090219-001AB18869cabd3fbd…
2020-11-12 02:37 UTC2020-11A090219-001AB1c0c555d07b60…
2019-12-14 00:12 UTC2019-12A090219-001AB13f01610625f2…
2019-09-15 20:21 UTC2019-09A090219-001AB1b00525d2431f…
2019-07-19 19:46 UTC2019-07A090219-001AB1ea99ee380514…
2024-03-16 18:09 UTC · 4 captures of this ZIP2024-03A090219-001AB16a51e52b5d6a…
2024-02-18 07:12 UTC2024-02A090219-001AB11c564ffb4f44…
2023-12-20 04:57 UTC2023-12A090219-001AB1ea1830bbd6c7…
2023-11-28 05:40 UTC · 2 captures of this ZIP2023-11A090219-001AB1a72a2bbeb626…
2023-10-25 00:34 UTC · 2 captures of this ZIP2023-10A090219-001AB19b2671bbb829…
2023-07-15 15:27 UTC · 2 captures of this ZIP2023-07A090219-001AB1a67488948f0b…
2023-06-13 01:57 UTC · 3 captures of this ZIP2023-06A090219-001AB13f0d92c62455…
2023-05-13 08:27 UTC2023-05A090219-001AB1053a50430f4f…
2023-01-26 05:58 UTC2023-01A090219-001AB13bdfa0b2c4d7…
2022-11-12 20:34 UTC · 5 captures of this ZIP2022-11A090219-001AB13a93d1ddd44b…

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 2 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
ClotrimazoleCLOTRIMAZOLERedpharm Drug53cafc9f-7761-83a9-e063-6294a90a34372026-06-09Warnings, Adverse reactionsExact identifier
ndc (package): 67296-2252-3
ndc (product): 67296-2252
ndc11 (package): 67296225203
spl id: 53cb3b8e-e8d2-fffc-e063-6294a90ac814
spl set id: 53cafc9f-7761-83a9-e063-6294a90a3437
ClotrimazoleCLOTRIMAZOLEGlenmark Pharmaceuticals Inc., USAf6898117-14f3-42d2-bc0e-d296add3ad702026-01-30Warnings, Adverse reactionsExact identifier
ndc (product): 68462-181

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.